LATEST NEWS IN PROSTATE CANCER
Breaking News: ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval
Today, the US FDA approved Erleada (apalutamide), an androgen receptor inhibitor created by Janssen Pharmaceuticals for the treatment of men with non-metastatic, castration-resistant prostate cancer. Erleada was approved after a priority review of...
An Update on Active Surveillance
Active Surveillance is often the best treatment choice for men with low-risk disease, but new thinking proposes that men with a favorable type of intermediate risk disease may also be candidates for this noninvasive management protocol. Laurence Klotz, MD, the leading expert in active surveillance, addresses this new thinking in this article.
XTANDI (enzalutamide): A New Treatment for Metastatic Castration-Resistant Prostate Cancer
Given enzalutamide’s unique and multi-targeted mechanism of action, its once a day oral administration, avoidance of accompanying requirement of a steroid, and its established safety and efficacy data, it appears to be a very promising therapy. Future studies should investigate both combination strategies with other approved prostate cancer drugs, as well as the potential role of enzalutamide in earlier stages of both CRPC and androgen-sensitive prostate cancer.
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer
Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5).